Does Tirapazamine (SR-4233) Have Any Cytotoxic or Sensitizing Effect on Three Human Tumour Cell Lines at Clinically Relevant Partial Oxygen Pressure?

References

• Adams G.E., Stratford I.J. Bioreductive drugs for cancer therapy: the search for tumour specificity. International Journal of Radiation Oncology, Biology and Physics 1994; 29: 231–238
   PubMed Web of Science ®Google Scholar
• Baker M.A., Zeman E.M., Hirst V.K., Brown J.M. Metabolism of SR-4233 by Chinese hamster ovary cells: the basis of selective hypoxic cytotoxicity. Cancer Research 1988; 48: 5947–5952
   PubMed Web of Science ®Google Scholar
• Biederman K.A., Brown J.M. Comparison between X-rays and SR-4233 for cytotoxicity and repair of potentially lethal damage in human cells. International Journal of Radiation Biology 1989; 56: 813–816
   PubMed Web of Science ®Google Scholar
• Brown J.M. SR-4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. British Journal of Cancer 1993; 67: 1163–1170
   PubMed Web of Science ®Google Scholar
• Brown J.M., Lemmon M.J. Tumour hypoxia can be exploited to preferentially sensitize tumours to fractionated irradiation. International Journal of Radiation Oncology, Biology and Physics 1991 a; 20: 457–461
   PubMed Web of Science ®Google Scholar
• Brown J.M., Lemmon M.J. A tumour-specific radiosensitizer active in fractionated radiation regimes. Radiotherapy and Oncology 1991 b; 20: 151–156, (suppl)
   PubMed Web of Science ®Google Scholar
• Bush R.S., Jenkin R.D.T., Allt W.E.C., Beale F.A., Bean H., Dembo A.J., Pringle J.F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. British Journal of Cancer 1978; 37(suppl. III)302–306
   Google Scholar
• Chaplin D.J., Durand R.E., Olive P.L. Acute hypoxia in tumours: implications for modifiers of radiation effects. International Journal of Radiation Oncology, Biology and Physics 1986; 12: 1279–1282
   PubMed Web of Science ®Google Scholar
• Chapman J.D. Measurement of tumour hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiotherapy and Oncology 1991; 20: 13–19
   PubMed Web of Science ®Google Scholar
• Coleman C.N. Hypoxia in tumours: a paradigm for the approach to biochemical and physiologic heterogeneity. Journal of the National Cancer Institute 1988; 80: 310–317
   PubMed Web of Science ®Google Scholar
• Costa A.K., Baker M.A., Brown J.M., Trudell J.R. In vitro hepatotoxicity of SR-4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumour agent. Cancer Research 1989; 49: 925–929
   PubMed Web of Science ®Google Scholar
• Dische S. Hypoxia and local tumour control. Part. 2. Radiotherapy and Oncology 1991; 20: 9–11
   PubMed Web of Science ®Google Scholar
• Fertil B., Malaise E.P. Inherent cellular radiosensitivity as a basic concept for human tumour radiotherapy. International Journal of Radiation Oncology, Biology and Physics 1981; 7: 621–629
   PubMed Web of Science ®Google Scholar
• Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H., Broder G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1988; 14: 831–838
   PubMed Web of Science ®Google Scholar
• Guichard M. Comparison of the radiobiological properties of human tumour xenografts and rodent tumours. International Journal of Radiation Biology 1989; 56: 583–586
   PubMed Web of Science ®Google Scholar
• Hoeckel M., Knoop C., Schlenger K., Vorndran B., Baussmann E., Mitze M., Knapstein P.G., Vaupel P. Intratumoural pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology 1993; 26: 45–50
   PubMed Web of Science ®Google Scholar
• Kennedy K.A. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Research 1987; 2: 181–194
   PubMed Web of Science ®Google Scholar
• Keohane A., Godden J., Stratford I.J., Adams G.E. The effects of three bioreductive drugs (mitomycin, RSU-1069 and SR-4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. British Journal of Cancer 1990; 61: 722–726
   PubMed Web of Science ®Google Scholar
• Koch C.J. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiation Research 1984; 97: 434–442
   PubMed Web of Science ®Google Scholar
• Koch C.J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Research 1993; 53: 3992–3997
   PubMed Web of Science ®Google Scholar
• Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scandinavian Journal of Clinical and Laboratory Investigation 1968; 106: 145–157
   Google Scholar
• Lambin P., Guichard M., Chavaudra N., Malaise E.P. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumour cell lines having different radiosensitivity. Radiotherapy and Oncology 1992; 24: 201–204
   PubMed Web of Science ®Google Scholar
• Lartigau E., Le Ridant A.M., Lambin P., Weeger P., Martin L., Sigal R., Lusinchi A., Lubionski B., Eschwege F., Guichard M. Oxygenation of head and neck tumours. Cancer 1993; 71: 2319–2325
   PubMed Web of Science ®Google Scholar
• Lartigau E., Martin L., Lambin P., Haie-Meder C., Gerbaulet A., Eschwege F., Guichard M. Mesure de la pression partielle en oxygène dans des tumeurs du col utérin. Bulletin du Cancer/Radiotherapie 1992; 79: 199–206
   Google Scholar
• Lin A.J., Cosby L.A., Shansky C.W., Sartorelli A.C. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. Journal of Medical Chemistry 1972; 15: 1247–1252
   PubMed Web of Science ®Google Scholar
• Minchinton A.I., Lemmon M.J., Tracy M., Pollart D.J., Martinez A.P., Brown J.M. Second-generation 1, 2, 4-benzotriazine 1, 4-di-N-oxide bioreductive anti-tumour agents: pharmacology and activity in vitro and in vivo. International Journal of Radiation Oncology, Biology and Physics 1992; 22: 701–705
   PubMed Web of Science ®Google Scholar
• Overgaard J. Importance of tumour hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiotherapy and Oncology 1992; 24: S64–S64
   PubMed Web of Science ®Google Scholar
• Rockwell S., Moulder J.E. Hypoxic fractions of human tumours xenografted into mice: a review. International Journal of Radiation Oncology, Biology and Physics 1990; 19: 197–202
   PubMed Web of Science ®Google Scholar
• Sakata K., Tak Kwok T., Murphy B.J., Laderoute K.R., Gordon G.R., Sutherland R.M. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. British Journal of Cancer 1991; 64: 809–814
   PubMed Web of Science ®Google Scholar
• Skarsgard L.D., Vinczan A., Skwarchuk M.W., Chaplin D.J. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro. International Journal of Radiation Oncology, Biology and Physics 1994; 29: 363–367
   PubMed Web of Science ®Google Scholar
• Teicher B.A., Lazo J.S., Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumour cell. Cancer Research 1981; 41: 73–81
   PubMed Web of Science ®Google Scholar
• Vaupel P. Oxygenation of human tumours. Strahlentherapy und Onkologie 1990; 166: 377–386
   PubMed Web of Science ®Google Scholar
• Weissberg J.B., Son Y.H., Papac R.J., Sasaki C., Fischer D.B., Lawrence R. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1989; 17: 3–9
   PubMed Web of Science ®Google Scholar
• Workman P., Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastases Reviews 1993; 12: 73–82
   PubMed Web of Science ®Google Scholar
• Zeman E.M., Brown J.M. Pre- and post-irradiation radiosensitization by SR-4233. International Journal of Radiation Oncology, Biology and Physics 1989; 61: 967–971
   Google Scholar
• Zeman E.M., Brown J.M. Aerobic radiosensitization by SR-4233 in rodent and human cells: mechanistic and therapeutic implications. International Journal of Radiation Biology 1991; 59: 117–131
   PubMed Web of Science ®Google Scholar
• Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology, Biology and Physics 1986; 12: 1239–1242
   PubMed Web of Science ®Google Scholar
• Zeman E.M., Hirst V.K., Lemmon M.J., Brown J.M. Enhancement of radiation-induced tumour cell killing by the hypoxic cell toxin SR-4233. Radiotherapy and Oncology 1988; 12: 209–218
   PubMed Web of Science ®Google Scholar
• Zeman E.M., Lemmon J.M., Brown J.M. Aerobic radiosensitization by SR-4233 in vitro and in vivo. International Journal of Radiation Oncology, Biology and Physics 1990; 18: 125–132
   PubMed Web of Science ®Google Scholar